Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING

NCT05331170 is registered in ClinicalTrials.gov with The University of Texas Medical Branch, Galveston as lead sponsor.

NCT NCT05331170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05331170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING
Lead sponsor
The University of Texas Medical Branch, Galveston
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2023
Completion date
May 1, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, asthma, cat allergy, healthy